The FDA on May 29, 2024, granted accelerated approval to RETEVMO® (Selpercatinib) for pediatric patients two years of age and older with RET-altered metastatic thyroid cancer or solid tumors. RETEVMO® is a product of Eli Lilly and Company.
Bottom Ad
Advertisement
Subscribe
